Current Assets
Accounts Receivable
Bristol-Myers Squibb Accounts Receivable decreased by 17.9% to $9.37B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 13.3%, from $10.80B to $9.37B. Over 5 years (FY 2020 to FY 2025), Accounts Receivable shows an upward trend with a 6.1% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
CategoryEfficiency
SignalContext dependent
VolatilityModerate
First reportedQ4 2014
Last reportedQ1 2026Apr 30, 2026
How to read this metric
Rapid growth relative to sales may indicate collection issues or aggressive revenue recognition; stability suggests efficient cash conversion.
Detailed definition
This represents the total amount owed to the company by customers for goods or services delivered, minus the allowance f...
Peer comparison
Standard metric for all companies with B2B or credit-based sales models.
Metric ID:
accounts_receivable_netHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $9.02B | $9.25B | $9.37B | $8.51B | $9.05B | $9.61B | $9.89B | $10.05B | $10.11B | $10.30B | $10.92B | $10.45B | $11.42B | $11.03B | $10.75B | $10.80B | $11.42B | $11.42B | $11.41B | $9.37B |
| QoQ Change | — | +2.5% | +1.3% | -9.2% | +6.4% | +6.2% | +2.8% | +1.7% | +0.6% | +1.9% | +6.0% | -4.3% | +9.3% | -3.5% | -2.5% | +0.5% | +5.7% | +0.1% | -0.1% | -17.9% |
| YoY Change | — | — | — | — | +0.4% | +4.0% | +5.5% | +18.1% | +11.7% | +7.2% | +10.5% | +3.9% | +13.0% | +7.0% | -1.6% | +3.4% | -0.1% | +3.6% | +6.2% | -13.3% |
Range$8.51B – $11.42B
CAGR+0.8%
Avg YoY Growth+5.0%
Median YoY Growth+4.7%
Current Streak2 quarters decline
Accounts Receivable at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's accounts receivable?
- Bristol-Myers Squibb (BMY) reported accounts receivable of $9.37B in Q1 2026.
- How has Bristol-Myers Squibb's accounts receivable changed year-over-year?
- Bristol-Myers Squibb's accounts receivable decreased by 13.3% year-over-year, from $10.80B to $9.37B.
- What is the long-term trend for Bristol-Myers Squibb's accounts receivable?
- Over 5 years (2020 to 2025), Bristol-Myers Squibb's accounts receivable has grown at a 6.1% compound annual growth rate (CAGR), from $8.50B to $11.41B.
- What does accounts receivable mean?
- The net amount of money owed by customers after accounting for potential non-payments.